H-1337 Ophthalmic Solution Phase 1/2

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

87 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-15

Study Completion Date

2018-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with elevated intraocular pressure (IOP).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05913232

Glaucoma Open-Angle Primary Ocular Hypertension

COMPLETED PHASE2

Study of AR-13324 in Patients With Elevated Intraocular Pressure

NCT01528787

Ocular Hypertension Open Angle Glaucoma

COMPLETED PHASE2

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

NCT01654484

Glaucoma and Ocular Hypertension

COMPLETED PHASE1/PHASE2

Open-Label Study of Safety of H1337 in Healthy Volunteers

NCT06572397

Glaucoma Open-Angle Primary Ocular Hypertension

COMPLETED PHASE1

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126

Open-angle Glaucoma or Ocular Hypertension

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study ALY337-201 will be a double-masked, randomized, placebo-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of H-1337 ophthalmic solution in subjects with ocular hypertension (OHT) or open angle glaucoma.

During screening, subjects who meet the preliminary inclusion/exclusion criteria will discontinue use of their ocular hypotensive therapy during the washout period. The washout duration will be dependent on the subject's pre-study ocular hypotensive therapy. Starting on Day 0, those who continue to meet the inclusions/exclusion criteria and the diurnal IOP criteria will be randomized into one of the treatments arms and dosing will be initiated, continuing for 28 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma, Open-Angle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double-masked, parallel

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double-masked containers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

H-1337 Placebo

Group Type PLACEBO_COMPARATOR

H-1337 Placebo

Intervention Type DRUG

H-1337 Placebo Vehicle

H-1337 [1]

H-1337 \[1\]

Group Type EXPERIMENTAL

H-1337 [1]

Intervention Type DRUG

H-1337 Ophthalmic Solution Concentration 1

H-1337 [2]

H-1337 \[2\]

Group Type EXPERIMENTAL

H-1337 [2]

Intervention Type DRUG

H-1337 Ophthalmic Solution Concentration 2

H-1337 [3]

H-1337 \[3\]

Group Type EXPERIMENTAL

H-1337 [3]

Intervention Type DRUG

H-1337 Ophthalmic Solution Concentration 3

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H-1337 Placebo

H-1337 Placebo Vehicle

Intervention Type DRUG

H-1337 [1]

H-1337 Ophthalmic Solution Concentration 1

Intervention Type DRUG

H-1337 [2]

H-1337 Ophthalmic Solution Concentration 2

Intervention Type DRUG

H-1337 [3]

H-1337 Ophthalmic Solution Concentration 3

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vehicle H-1337 conc 1 H-1337 conc 2 H-1337 conc 3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age or older.
2. Diagnosis of bilateral primary open angle glaucoma or ocular hypertension.
3. One qualifying IOP criteria after washout:

• Baseline (Day 0) at T0 (T0 = 8 am ± 30 min) IOP ≥ 23 mmHg in the study eye.
4. IOP criteria after washout ≤ 32 mmHg oculus uterque (OU) at all time points.
5. Best-corrected visual acuity (BCVA) in both eyes of 20/200 or better on Snellen, equivalent to + 1.0 log Mar.
6. Able and willing to sign informed consent, follow study instructions and complete all study visits.
7. As applicable, must be willing to discontinue the use of all ocular hypotensive medication(s) in both eyes prior to receiving the study medication and for the entire course of the study.
8. Able to self-administer or have a caretaker administer study eye drops.

Exclusion Criteria

Ophthalmic:

Exclude subjects with:

1. Closed or very narrow angles (Grade 0-1) (see Section 5, gonioscopy) or those the investigator judges as occludable and/or with evidence of peripheral anterior synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to Screening Visit in either eye. (Patent laser iridotomy with Grade 1-2 angles is acceptable in either eye, providing the PAS criteria are still met).
2. Previous glaucoma intraocular surgery in either eye. Prior laser trabeculoplasty (ALT or SLT) in either eye is allowed if performed more than 6 months prior to Screening Visit.
3. Any non-glaucoma intraocular surgery within 3 months prior to Screening Visit in either eye.
4. Intraocular laser surgery such as laser capsulotomy, laser iridotomy, and/or retinal laser within 1 month prior to Screening Visit in either eye.
5. Significant media opacity in either eye that would impede adequate posterior segment examination.
6. Contraindications to pupil dilation in either eye.
7. Other forms of glaucoma such as primary congenital, juvenile onset, chronic angle closure, and secondary glaucoma of any type including steroid-induced, inflammation-induced, or exfoliation glaucoma in either eye. Pigment dispersion syndrome/glaucoma is permitted in either eye.
8. Clinically significant corneal dystrophy, epithelial or endothelial disease, corneal irregularities or scarring that, in the investigator's judgment, would impede an accurate measurement of IOP or visualization of intraocular anatomy in the study eye.
9. History of refractive surgery in either eye (i.e., radial keratotomy, photorefractive keratectomy, LASIK).
10. History of corneal cross-linking procedure in either eye.
11. Unwillingness to be contact lens free during study participation.
12. Any history of uveitis, keratitis, or scleritis in either eye.
13. Any history of penetrating ocular trauma in either eye.
14. History within 3 months prior to Screening Visit of clinically significant moderate or severe chronic or active blepharitis, ocular dermatitis, or recent ocular conjunctivitis and/or ocular inflammation in either eye. Mild blepharitis, hyperemia (due to prostaglandin use) and/or blepharitis, and/or mild inactive seasonal allergic conjunctivitis and non-infective dermatitis are acceptable.
15. Corneal thickness \< 480 or \> 620 µm in the study eye. Pachymetry measurement within 6 months prior to Screening Visit is acceptable.
16. Advanced or severe glaucoma with progressive visual field loss and/or optic nerve changes in either eye that, in the investigator's best judgment, prevent safe withdrawal from treatment for the time periods required in this protocol.
17. Progressive retinal (including, but not limited to worsening dry age-related macular degeneration (AMD), presence of active wet AMD, or unstable diabetic retinopathy) or optic nerve disease in either eye from any cause other than glaucoma.
18. Any prior intravitreal steroid injection in either eye.
19. Sub-tenon's, sub-conjunctival or periocular steroid injections within the 6 months prior to Screening Visit in either eye.
20. Any use of ocular topical corticosteroids in either eye within 7 days, or chronic (as determined by the investigator) topical steroids within 28 days prior to Baseline and ensuing trial participation.
21. Known hypersensitivity to any component of the H-1337 formulation, including benzalkonium chloride, or to topical anesthetics or diagnostic drops used during the study.
22. Any ocular, condition that, in the investigator's judgment, could prevent the subject from safe participation the study.
23. Planned ocular surgery or intraocular injection procedure in either eye during study participation.

General/Systemic:
24. Participation in a clinical study with use of any investigational drug or treatment within 30 days prior to Baseline (Day 0).
25. Clinically significant abnormalities in: laboratory tests, physical examination, vital signs and/or ECG at Screening Visit. If in the investigator's judgment a subject with clinically significant abnormalities is appropriate for enrollment in the study, a discussion between the investigator and the Medical Monitor must occur and be documented prior to enrollment of this subject in the study.
26. Clinically significant systemic, psychiatric or psychological disease (for example, renal, hepatic, uncontrolled diabetes, uncontrolled blood pressure, autoimmune disorders, psychiatric disorders, endocrine disorders, or any other disorders) or dependency which, in the investigator's judgment, would be unsafe and interfere with interpretation of the study results or the subject's ability to comply with the study requirements.
27. Anticipated changes or initiation of medications which might affect IOP and/or systemic blood pressure within 7 days prior to Baseline/Day 0 (e.g., oral anti-hypertensives such as sympathomimetic agents, beta-adrenergic blocking agents, alpha agonists, alpha adrenergic blocking agents, calcium channel blockers, angiotensin converting enzyme inhibitors; \[diuretics are allowed\]), and 2 months prior to Baseline/Day 0 for corticosteroids (i.e., oral, nasal, topical \[dermal, mucosal\], and/or inhaled corticosteroids). If there are no further anticipated changes in medications that could affect IOP and/or systemic blood pressure, then once the subject is stable on their new dose of medication for the required time period, the subject may complete the Baseline Visit, assuming that all other screening requirements are met. Medications used on an adjustable or sliding scale based on testing results are allowed.
28. Known history of Hepatitis B + C, HIV+, or AIDS and/or inadequate venous access.
29. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative serum pregnancy test result at Screening Visit and a negative urine and serum pregnancy test at Baseline (Day 0) prior to randomization in the study and must not intend to become pregnant during the study.
30. History of drug or alcohol abuse within the last 5 years.
31. Related to site study staff and/or site employees.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No